Clinical Data AstraZeneca lung drug gets ‘surprise’ win in COPD trials BioPharma DiveThe treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent.Clinical DataRespiratoryRead full story pharminent March 27, 2026 (Last updated: March 30, 2026) BioPharma Dive The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent. Clinical DataRespiratoryRead full story Post navigation Previous: Novartis targets Xolair successor in buyout of startup ExcellergyNext: Otsuka picks up PTSD drug with $700M Transcend buy Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
